Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced.
GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.
Treatment with tyrosine kinase inhibitors does not appear to significantly impair health-related quality of life in Japanese patients with metastatic renal cell carcinoma, say researchers.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program.
Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.
Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.
Positron emission tomography could be used to predict the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy within a couple of weeks of a patient beginning treatment, research suggests.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.
Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the disease, they say.
VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.